MedTrace Logo

A Study of KH607 as Monotherpy in Adults Participants With Major Depressive Disorder

NCT07741240 · Status: NOT_YET_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 232

Last updated 2026-08-03

No results posted yet for this study

Summary

This trial includes a short-term study and a long-term study. The short-term study is a multicenter, randomized, double-blind, placebo-controlled parallel-group study with a 6-week duration. The long-term study is a multicenter, open-label, single-arm study with a maximum duration of 27 weeks.

Conditions

  • Major Depressive Disorder (MDD)

Interventions

DRUG

KH607 tablets

oral 20mg, once daily for 21 days

DRUG

placebo

oral, once daily for 21 days

DRUG

KH607 tablets

oral 20mg, once daily for 21 days

Sponsors & Collaborators

  • Chengdu Kanghong Pharmaceutical Group Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-07-31
Primary Completion
2027-12-31
Completion
2027-12-31

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07741240 on ClinicalTrials.gov